This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Tuesday's Small-Cap Winners & Losers

Align Technology (ALGN) was surging more than 20% after the California-based maker of invisible braces said it lost only $11.7 million excluding items, or 19 cents a share, in all of 2006. Analysts polled by Thomson Financial were looking for a 43-cent per-share loss. Revenue, which came to $206.4 million, was almost in line with the mean target. In 2005 the company had earned $1.4 million, or 2 cents a share, on slightly higher revenue of $207.1 million. Shares were gaining $2.87 to $16.64.

Theragenics (TGX), which makes medical devices for cancer treatment and surgery, swung to a fourth-quarter and full-year profit -- successes that CEO M. Christine Jacobs attributes to a far more diversified line of products than what the company previously had. Revenue grew 30% to $14.8 million for the quarter and 22% to $54.1 million for the year, representing the company's highest-ever quarterly and annual sales, respectively. Full-year earnings came to $6.6 million, or 20 cents a share, up sharply from a 2005 loss of $29 million, or 93 cents a share. The Buford, Ga., company was trading up 71 cents, or 20.5%, to $4.17.

Compugen (CGEN) struck a deal with fellow Israeli company Teva (TEVA) for jointly discovering biomarkers that can indicate drug toxicity prior to clinical stages of drug development. First on the agenda will be those signifying nephrotoxicity, or toxicity of the kidney cells. Financial terms, if any, weren't disclosed, but Teva will have a license to use any discoveries for research and development, and Compugen will retain rights for commercialization and internal use. Compugen shares were climbing 33 cents, or 11.6%, to $3.18 in recent trading. Teva shares were unchanged.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs